in vitro diagnostics; diagnosing infectious diseases; cancer screening and monitoring and cardiovascular emergencies.
A global leader in in vitro diagnostics for more than 50 years, bioMérieux has always been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide. Today, in more than 150 countries through 43 subsidiaries and a large network of distributors, bioMérieux provides diagnostic solutions that improve patient health and ensure consumer safety. With its 10,400 employees worldwide, bioMérieux achieved € 2.3 billion in sales in 2017.
bioMérieux develops and produces in vitro diagnostic solutions (systems, reagents and software) for private and hospital laboratories, mainly for the diagnosis of infectious diseases. The results obtained from a patient sample (blood, urine, stool, cerebrospinal fluid, saliva, etc.) provide doctors with information to support their decisions. For 25 years, bioMérieux has also applied the expertise acquired in the clinical sector to meet industrial microbiology needs, making it possible to manage contamination risks in agri-food, pharmaceutical and cosmetic products, at each step of the production chain.
